---
id: 246
title: Candida albicans and Candidiasis
category: organisms
subcategory: fungi
tags: [Candida, candidemia, fluconazole, echinocandin, thrush, invasive-candidiasis]
difficulty: medium
---

## Question

What are key clinical syndromes and treatment considerations for *Candida*? Use **"Candidemia: Echinocandin First-Line, Fluconazole Step-Down, Remove Central Lines"** framework.

## Answer

### **Species:**

***C. albicans*** (50-60% of invasive candidiasis)
***C. glabrata*** (15-20%, often fluconazole-resistant)
***C. parapsilosis*** (10-15%, catheter-related, neonates)
***C. tropicalis*** (10%, neutropenic patients, high mortality)
***C. auris*** (emerging, multidrug-resistant)

### **Key Clinical Syndromes:**

**Mucocutaneous:**
- **Oropharyngeal candidiasis (thrush):** White plaques, HIV CD4 <200
- **Esophageal candidiasis:** Odynophagia, HIV CD4 <100
- **Vulvovaginal candidiasis:** Discharge, pruritus (common, NOT always immunocompromised)
- **Chronic mucocutaneous candidiasis:** Genetic defects (AIRE, STAT1, CARD9)

**Candidemia/Invasive Candidiasis:**
- **Bloodstream infection** (often CVC-related)
- **Endocarditis** (IVDU, prosthetic valves)
- **Endophthalmitis** (hematogenous, post-surgical)
- **Disseminated candidiasis:** Hepatosplenic, chronic disseminated (neutropenia)
- **High mortality** (30-40%)

**Urinary:**
- **Candiduria:** Often catheter-related, colonization vs infection

**Intra-Abdominal:**
- **Peritonitis** (post-surgical, perforated viscus)

### **Treatment:**

**Oropharyngeal Candidiasis (Thrush):**
- **Fluconazole 100-200mg PO daily × 7-14 days** (first-line)
- **Clotrimazole troches 10mg PO 5×/day × 7-14 days** (topical)
- **Nystatin suspension 400,000-600,000 units swish/swallow QID** (less effective)

**Esophageal Candidiasis:**
- **Fluconazole 200-400mg PO/IV daily × 14-21 days** (first-line)
- **Refractory:** Echinocandin (micafungin 150mg IV daily, caspofungin 70mg × 1 → 50mg daily)
- **Voriconazole 200mg PO BID** (alternative)

**Vulvovaginal Candidiasis:**
- **Uncomplicated:** Fluconazole 150mg PO × 1 (single dose) OR topical azole (miconazole, clotrimazole) × 3-7 days
- **Recurrent (≥4 episodes/year):** Fluconazole 150mg PO weekly × 6 months (suppression)

**Candidemia/Invasive Candidiasis:**

**Initial Therapy (Empiric):**
- **Echinocandin** (first-line, especially if critically ill, azole-exposed, or *C. glabrata* risk):
  - **Micafungin 100mg IV daily**
  - **Caspofungin 70mg IV × 1 → 50mg IV daily**
  - **Anidulafungin 200mg IV × 1 → 100mg IV daily**

**Step-Down (After Clinical Improvement + Susceptibilities):**
- **Fluconazole 400-800mg IV/PO daily** (if susceptible, stable)
- **NOT for *C. glabrata*, *C. krusei*** (inherent resistance/reduced susceptibility)

**Duration:**
- **14 days** after first negative blood culture + clinical improvement
- **Longer if:** Metastatic foci (endophthalmitis, endocarditis, osteomyelitis)

**Source Control:**
- **Remove central venous catheter** (improves outcomes, reduces mortality)
- **Within 48h** of positive blood culture

**Ophthalmologic Exam:**
- **Dilated fundoscopic exam within 1 week** (r/o endophthalmitis)
- **All patients with candidemia**

**Candida Endocarditis:**
- **Echinocandin** (micafungin, caspofungin) OR **liposomal amphotericin B 3-5 mg/kg IV daily**
- **± Fluconazole 400-800mg daily** (step-down if susceptible, after initial echinocandin)
- **Surgical valve replacement** (almost always required, medical therapy alone insufficient)
- **Duration:** ≥6 weeks after surgery (or indefinitely if surgery not performed)

**Candida Endophthalmitis:**
- **Fluconazole 400-800mg PO daily × 4-6 weeks** (good vitreous penetration)
- **± Intravitreal amphotericin B** (if severe)
- **Vitrectomy** if severe

**Candiduria:**
- **Asymptomatic:** Do NOT treat (colonization, resolves with catheter removal)
- **Symptomatic (cystitis, pyelonephritis):** Fluconazole 200-400mg daily × 7-14 days
- **Urologic procedures:** Consider prophylaxis if candiduria present

**Intra-Abdominal Candidiasis:**
- **Echinocandin** (micafungin 100mg IV daily) × 2 weeks after source control
- **Fluconazole 400-800mg daily** (if stable, susceptible)

**Chronic Disseminated (Hepatosplenic) Candidiasis:**
- **Fluconazole 400-800mg daily × months** (until lesions resolve, immune reconstitution)
- **Common in neutropenic patients** (leukemia, transplant)

### **Antifungal Agents:**

**Echinocandins:**
- **Mechanism:** Inhibit β-(1,3)-D-glucan synthase (cell wall)
- **Pros:** Broad-spectrum (except *C. parapsilosis* slightly reduced), fungicidal, well-tolerated
- **First-line for candidemia**

**Fluconazole:**
- **Mechanism:** Inhibit ergosterol synthesis (cell membrane)
- **Pros:** Excellent bioavailability (PO = IV), good CNS/urine penetration, fungistatic
- **Cons:** Resistance (*C. glabrata*, *C. krusei*), drug interactions (CYP450)

**Amphotericin B:**
- **Mechanism:** Binds ergosterol (forms pores in membrane)
- **Pros:** Broad-spectrum, fungicidal
- **Cons:** Nephrotoxic, infusion reactions
- **Use:** Refractory cases, liposomal formulation preferred (less toxic)

### **Resistance:**

***C. glabrata*:**
- **Dose-dependent fluconazole susceptibility** (often resistant)
- **Treat with echinocandin**

***C. krusei*:**
- **Intrinsic fluconazole resistance**
- **Treat with echinocandin or voriconazole**

***C. auris*:**
- **Multidrug-resistant** (fluconazole, amphotericin B resistance common)
- **Treat with echinocandin**
- **Infection control critical** (transmission in healthcare)

### **Special Populations:**

**Neutropenic Patients:**
- **Empiric antifungal** if persistent fever despite antibiotics (consider echinocandin or liposomal amphotericin B)
- **Chronic disseminated candidiasis** (hepatosplenic) common

**Neonates:**
- ***C. parapsilosis* common** (catheter-related)
- **Amphotericin B deoxycholate 1 mg/kg IV daily** (echinocandins less experience in neonates)

## Key Points

### **Candidemia = Echinocandin First-Line:**
- **Micafungin 100mg IV daily** (preferred)
- **Step-down to fluconazole** if susceptible, stable

### **Remove Central Line:**
- **Within 48h** (improves outcomes)

### **Ophthalmology Exam:**
- **All candidemia patients** (within 1 week, r/o endophthalmitis)

### **14 Days After First Negative Culture:**
- **+ Clinical improvement**

### ***C. glabrata*, *C. krusei* = Fluconazole-Resistant:**
- **Use echinocandin**

### **Clinical Pearls:**
- **Candidemia:** Echinocandin (micafungin 100mg IV daily) first-line
- **Remove central line** within 48h
- **Ophthalmology exam** (all candidemia, within 1 week)
- **Duration:** 14 days after first negative culture + clinical improvement
- **Fluconazole step-down** if susceptible, stable
- ***C. glabrata/krusei*:** Fluconazole-resistant (use echinocandin)

## Sources

- [IDSA: Candidiasis Guidelines 2024]
- [CID: Candidemia Management 2024]

## Media

N/A
